Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins

Journal of Interferon and Cytokine Research

Volumn 30, Issue 3, 2010, Pages 123-133

  Bandi, Prasanthi ^a   Pagliaccetti, Nicole E ^a   Robek, Michael D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOPLASM PROTEIN; IMMUNOMODULATING AGENT; INTERFERON; INTERFERON 3; PROTEIN B18R; PROTEIN E3L; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INHIBITION KINETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOPOXVIRUS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMALLPOX VIRUS; VACCINIA VIRUS; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERONS; MICE; RECEPTOR, INTERFERON ALPHA-BETA; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; VACCINIA; VACCINIA VIRUS; VARIOLA VIRUS; VESICULOVIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

ORTHOPOXVIRUS; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 77949795872     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2009.0049     Document Type: Article

References (53)

1. Alcami A, Smith GL. 1995. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 69(8):4633-4639.
2. Alcami A, Symons JA, Smith GL. 2000. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 74(23):11230-11239.
3. Amicone L, Spagnoli FM, Spath G, Giordano S, Tommasini C, Bernardini S, De Luca V, Della Rocca C, Weiss MC, Comoglio PM, Tripodi M. 1997. Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO J 16(3):495-503.
4. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, Dagnaes-Hansen F, Thomsen AR, Chen Z, Haugen H, Klucher K, Paludan SR. 2008. An important role for type III interferon (IFNlambda/ IL-28) in TLR-induced antiviral activity. J Immunol 180(4):2474-2485.
5. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. 2006a. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80(9): 4501-4509.
6. Ank N, West H, Paludan SR. 2006b. IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res 26(6):373-379.
7. Arsenio J, Deschambault Y, Cao J. 2008. Antagonizing activity of vaccinia virus E3L against human interferons in Huh7 cells. Virology 377(1):124-132.
8. Balachandran S, Roberts PC, Brown LE, Truong H, Pattnaik AK, Archer DR, Barber GN. 2000. Essential role for the dsRNAdependent protein kinase PKR in innate immunity to viral infection. Immunity 13(1):129-141.
9. Bartlett NW, Buttigieg K, Kotenko SV, Smith GL. 2005. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol 86(Pt 6):1589-1596.
10. Beattie E, Denzler KL, Tartaglia J, Perkus ME, Paoletti E, Jacobs BL. 1995. Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol 69(1):499-505.
11. Brand S, Zitzmann K, Dambacher J, Beigel F, Olszak T, Vlotides G, Eichhorst ST, Goke B, Diepolder H, Auernhammer CJ. 2005. SOCS-1 inhibits expression of the antiviral proteins 2′,5′-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun 331(2):543-548.
12. Brandt TA, Jacobs BL. 2001. Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J Virol 75(2):850-856.
13. Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY. 2004. Effi cacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318(2):474-481.
14. Chang HW, Jacobs BL. 1993. Identifi cation of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA. Virology 194(2):537-547.
15. Chang HW, Watson JC, Jacobs BL. 1992. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, doublestranded RNA-dependent protein kinase. Proc Natl Acad Sci USA 89(11):4825-4829.
16. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, Cella M, Lande R, Uze G. 2004. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 34(3):796-805.
17. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 270(27):15974-15978.
18. Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, Pomerantz RJ. 2006. siRNA targeting vaccinia virus doublestranded RNA binding protein [E3L] exerts potent antiviral effects. Virology 348(2):489-497.
19. Di Giulio DB, Eckburg PB. 2004. Human monkeypox: an emerging zoonosis. Lancet Infect Dis 4(1):15-25.
20. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. 2004. The expanded family of class II cytokines that share the IL-10 receptor- 2 (IL-10R2) chain. J Leukoc Biol 76(2):314-321.
21. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM. 2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44(4):896-906.
22. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. 2003. Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 37(2):251-271.
23. Guerra S, Caceres A, Knobeloch KP, Horak I, Esteban M. 2008. Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog 4(7):e1000096.
24. Haga IR, Bowie AG. 2005. Evasion of innate immunity by vaccinia virus. Parasitology 130(Suppl):S11-S25.
25. Huang J, Smirnov SV, Lewis-Antes A, Balan M, Li W, Tang S, Silke GV, Putz MM, Smith GL, Kotenko SV. 2007. Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc Natl Acad Sci USA 104(23): 9822-9827.
26. Kim YG, Muralinath M, Brandt T, Pearcy M, Hauns K, Lowenhaupt K, Jacobs BL, Rich A. 2003. A role for Z-DNA binding in vaccinia virus pathogenesis. Proc Natl Acad Sci USA 100(12):6974-6979.
27. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69-77.
28. Lane JM, Millar JD, Neff JM. 1971. Smallpox and smallpox vaccination policy. Annu Rev Med 22:251-272.
29. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV. 2006. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 66(8):4468-4477.
30. Mann BA, Huang JH, Li P, Chang HC, Slee RB, O'Sullivan A, Anita M, Yeh N, Klemsz MJ, Brutkiewicz RR, Blum JS, Kaplan MH. 2008. Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons. J Interferon Cytokine Res 28(6):367-380.
31. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM. 2006. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131(6):1887-1898.
32. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. 2005. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 31(2):109-118.
33. Najarro P, Traktman P, Lewis JA. 2001. Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol 75(7):3185-3196.
34. Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, Hruby DE, Jordan R. 2008. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res 79(2):121-127.
35. Onoguchi K, Yoneyama M, Takemura A, Akira S, Taniguchi T, Namiki H, Fujita T. 2007. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 282(10):7576-7581.
36. Osterlund P, Veckman V, Siren J, Klucher KM, Hiscott J, Matikainen S, Julkunen I. 2005. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J Virol 79(15):9608-9617.
37. Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, Robek MD. 2008. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem 283(44):30079-30089.
38. Parker S, Touchette E, Oberle C, Almond M, Robertson A, Trost LC, Lampert B, Painter G, Buller RM. 2008. Effi cacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res 77(1): 39-49.
39. Robek MD, Boyd BS, Chisari FV. 2005. Lambda interferon inhibits Hepatitis B and C virus replication. J Virol 79(6):38851-43854
40. Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron C, Sypula J, Nazarian SH, Lucas A, McFadden G. 2003. Poxviruses and immune evasion. Annu Rev Immunol 21:377-423.
41. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4(1):63-68.
42. Shors ST, Beattie E, Paoletti E, Tartaglia J, Jacobs BL. 1998. Role of the vaccinia virus E3L and K3L gene products in rescue of VSV and EMCV from the effects of IFN-alpha. J Interferon Cytokine Res 18(9):721-729.
43. Smith GL, Chan YS. 1991. Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J Gen Virol 72(Pt 3):511-518.
44. Smith EJ, Marie I, Prakash A, Garcia-Sastre A, Levy DE. 2001. IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or Ikappa B kinase but is blocked by Vaccinia virus E3L protein. J Biol Chem 276(12):8951-8957.
45. Stojdl DF, Abraham N, Knowles S, Marius R, Brasey A, Lichty BD, Brown EG, Sonenberg N, Bell JC. 2000. The murine doublestranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J Virol 74(20):9580-9585.
46. Symons JA, Alcami A, Smith GL. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specifi city. Cell 81(4):551-560.
47. Thacore HR, Youngner JS. 1973. Rescue of vesicular stomatitis virus from interferon-induced resistance by superinfection with vaccinia virus. I. Rescue in cell cultures from different species. Virology 56(2):505-511.
48. Weaver JR, Shamim M, Alexander E, Davies DH, Felgner PL, Isaacs SN. 2007. The identifi cation and characterization of a monoclonal antibody to the vaccinia virus E3 protein. Virus Res 130(1-2):269-274.
49. Xiang Y, Condit RC, Vijaysri S, Jacobs B, Williams BR, Silverman RH. 2002. Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J Virol 76(10):5251-5259.
50. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol 79(20):13139-13149.
51. Zhang P, Jacobs BL, Samuel CE. 2008. Loss of protein kinase PKR expression in human HeLa cells complements the vaccinia virus E3L deletion mutant phenotype by restoration of viral protein synthesis. J Virol 82(2):840-848.
52. Zhang P, Langland JO, Jacobs BL, Samuel CE. 2009. Protein kinase PKR-dependent activation of mitogen activated protein kinases occurs through mitochondrial adapter IPS-1 and is antagonized by vaccinia virus E3L. J Virol 83(11):5718-5725.
53. Zhang P, Samuel CE. 2008. Induction of protein kinase PKRdependent activation of interferon regulatory factor 3 by vaccinia virus occurs through adapter IPS-1 signaling. J Biol Chem 283(50):34580-34587.